PrognomIQ, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2026 | $12 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2025 | $10 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Aug 2024 | $34 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
PrognomIQ, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).
SEC Form D · Jan 2026
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jan 2026
That is all the official record says: PrognomIQ, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, Jun 2026) | SEC Form N-PORT |
| Select Medical Technology and Devices Portfolio | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| Fidelity Growth Company Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| Fidelity Growth Company K6 Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| Fidelity Series Growth Company Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| Science & Technology Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| T. Rowe Price Health Sciences Portfolio | Fund or asset manager | not stated | not stated | Holds shares (fund report, Jun 2026) | SEC Form N-PORT |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 10 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian B. Koh, M.D. | Executive officer | Jan 2026 |
| Bruce B. Wilcox, Ph.D. | Executive officer | Jan 2026 |
| David L. Siewers | Executive officer | Jan 2026 |
| Philip Ma, Ph.D. | Executive officer | Jan 2026 |
| Joel Kaufman | Executive officer | Aug 2025 |
| Brian Koh, M.D. | Executive officer | Aug 2024 |
| David Siewers | Executive officer | Aug 2024 |
| Isaac B. Ro, Ph.D. | Director | Jan 2026 |
| Mark B. McClellan, M.D., Ph.D. | Director | Jan 2026 |
| Omid C. Farokhzad, M.D. | Director | Jan 2026 |
| Philip Ma, Ph.D. | Director | Jan 2026 |
| Rajesh B. Garg, M.D. | Director | Jan 2026 |
| Tomer C. Berkovitz, Ph.D. | Director | Jan 2026 |
| Isaac Ro | Director | Aug 2024 |
| Mark McClellan, M.D., Ph.D. | Director | Aug 2024 |
| Omid Farokhzad, M.D. | Director | Aug 2024 |
| Rajesh Garg | Director | Aug 2024 |
| Tomer Berkovitz, Ph.D. | Director | Aug 2024 |